Investigational drug · Phase 3
BHV-1300
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Graves Disease, Graves' Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "BHV-1300"
First trial start
2026
Jun 26, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BHV-1300", any sponsor or status.
Conditions studied
As listed on its trial records.
- Graves Disease
- Graves' Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BHV-1300" as an intervention, largest first.
- An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' DiseasePivotal-lookingNot yet recruiting
Biohaven Therapeutics Ltd.Industry
NCT07901244 · 356 participants (planned) · Start Oct 2026 · Primary completion Dec 2028
Drug: BHV-1300 · For: Graves' Disease
- Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' DiseasePivotal-lookingRecruiting
Biohaven Therapeutics Ltd.Industry
NCT07661056 · 300 participants (planned) · Start Jun 26, 2026 · Primary completion Jan 2028
Drug: BHV-1300; Placebo · For: Graves Disease
Sites: Tucson, Arizona; Burbank, California; Huntington Beach, California · 63 sites in all
- Study of BHV-1300 in Graves' DiseaseRecruiting
Biohaven Therapeutics Ltd.Industry
NCT06980649 · 15 participants (planned) · Start Aug 21, 2025 · Primary completion Sep 2027
Drug: BHV-1300 · For: Graves Disease
Sites: South Gate, California; Miami, Florida; Columbus, Georgia · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Graves Disease
- BatoclimabIMVT-1401Phase 33 trials
Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.